We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is als... YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminum-free lyophilized rabies vaccine that was launched in China. Show more
Ask ADVFN Intelligence (AI)
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance PR Newswire BEIJING, Dec. 19, 2024 Achieved total revenue of RMB...
BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the...
GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global leader in the discovery, development...
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire GAITHERSBURG, Md., Oct. 29, 2024 GAITHERSBURG, Md., Oct. 29, 2024 /PRNewswire/ -- LakeShore Biopharma...
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine PR Newswire GAITHERSBURG, Md., Oct. 25, 2024 GAITHERSBURG, Md., Oct. 25, 2024...
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance PR Newswire GAITHERSBURG, Md., Oct. 8, 2024 GAITHERSBURG, Md., Oct. 8, 2024...
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation PR Newswire GAITHERSBURG, Md., Sept. 27, 2024 GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/...
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 PR Newswire GAITHERSBURG, Md., Sept. 10, 2024 GAITHERSBURG, Md., Sept. 10, 2024 /PRNewswire/...
LakeShore Biopharma Announces Leadership Transitions PR Newswire GAITHERSBURG, Md., Sept. 4, 2024 GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB...
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 PR Newswire GAITHERSBURG, Md., Aug. 15, 2024 Gross margin increased to 79.5%; product pipeline continues to advance Company...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.69 | 29.8701298701 | 2.31 | 3 | 2.101 | 16845 | 2.58103387 | CS |
| 4 | 0.43 | 16.7315175097 | 2.57 | 3.99 | 2.101 | 16285 | 2.88503903 | CS |
| 12 | -5.4 | -64.2857142857 | 8.4 | 8.6 | 1.88 | 63177 | 4.26701619 | CS |
| 26 | -3.8 | -55.8823529412 | 6.8 | 8.6 | 1.88 | 48926 | 4.9177163 | CS |
| 52 | -7.9 | -72.4770642202 | 10.9 | 11.2 | 1.88 | 50900 | 5.44847265 | CS |
| 156 | -7.9 | -72.4770642202 | 10.9 | 11.2 | 1.88 | 50900 | 5.44847265 | CS |
| 260 | -7.9 | -72.4770642202 | 10.9 | 11.2 | 1.88 | 50900 | 5.44847265 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
